DMRA
Strong SellSinkerDamora Therapeutics, Inc. · Healthcare · United States · $1.3B
$20.24 +3.5% · close 7 Oct · scored 9 Oct
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
Read our full research report on DMRA (Apr 2026), freeDoes StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
ABOUT DAMORA THERAPEUTICS, INC.
Read
Damora Therapeutics, Inc. is a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for treating various diseases. Its competitive strength derives from its proprietary scientific platforms, intellectual property portfolio, and specialized research capabilities. As a clinical-stage biotech firm, its value is significantly tied to the progress and successful outcomes of its drug pipeline through clinical trials and regulatory approvals.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — |
| EPS | -1.01 | -0.64 | -0.40 | -0.10 | — | -0.26 |
| Shares | 61.6M | 61.6M | 61.6M | 61.6M | 0.0% | 61.7M |
| Debt | 0.8M | 0.2M | 73.0K | 68.0K | -56.1% | — |
| Equity | 61.8M | 32.3M | 15.8M | 240.4M | 57.3% | — |
| Op CF | -42.9M | -36.9M | -18.6M | -6.7M | — | -44.5M |
| Inv CF | 12.4M | 22.3M | 11.7M | -17.4M | — | — |
| Fin CF | 0.5M | 2.9M | 0 | 266.8M | — | — |
Swung more than 100% of stocks we rank over the past year (472% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DMRA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| DMRA | Damora Therapeutics, Inc.(you) | $1.3B | 12 | Strong Sell |
| AVLN | Avalyn Pharma Inc. | $1.3B | 12 | Strong Sell |
| SPTX | Seaport Therapeutics, Inc. | $1.1B | 13 | Strong Sell |
| INBX | Inhibrx Biosciences, Inc. | $1.5B | 12 | Strong Sell |
| TRAX | First Tracks Biotherapeutics, Inc. | $1.3B | 15 | Strong Sell |
| KARD | Kardigan, Inc. | $1.4B | 15 | Strong Sell |
| BCAX | Bicara Therapeutics Inc. | $1.4B | 15 | Strong Sell |
| VOR | Vor Biopharma Inc. | $1.1B | 15 | Strong Sell |
| RARE | Ultragenyx Pharmaceutical Inc. | $1.5B | 10 | Strong Sell |
| TYRA | Tyra Biosciences, Inc. | $1.6B | 12 | Strong Sell |
Peer medians: ROE -30.9% · P/E 25.1x · Gross margin 63.4%
Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.